For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $24.01 in the prior trading day, Biolife Solutions Inc (NASDAQ: BLFS) closed at $24.03, up 0.08%. In other words, the price has increased by $0.08 from its previous closing price. On the day, 0.53 million shares were traded. BLFS stock price reached its highest trading level at $24.88 during the session, while it also had its lowest trading level at $23.57.
Ratios:
Our goal is to gain a better understanding of BLFS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 14.65 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 106.54. For the most recent quarter (mrq), Quick Ratio is recorded 3.64 and its Current Ratio is at 4.66. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.03.
On September 30, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $29.
On April 04, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $22.Jefferies initiated its Buy rating on April 04, 2024, with a $22 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 11 ’25 when DE GREEF RODERICK sold 35,417 shares for $26.15 per share. The transaction valued at 926,155 led to the insider holds 454,581 shares of the business.
DE GREEF RODERICK sold 33,418 shares of BLFS for $864,858 on Nov 12 ’25. The President and CEO now owns 421,163 shares after completing the transaction at $25.88 per share. On Nov 13 ’25, another insider, DE GREEF RODERICK, who serves as the President and CEO of the company, sold 31,165 shares for $25.33 each. As a result, the insider received 789,409 and left with 389,998 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BLFS now has a Market Capitalization of 1156997632 and an Enterprise Value of 1098720512. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.55 while its Price-to-Book (P/B) ratio in mrq is 3.26. Its current Enterprise Value per Revenue stands at 10.971 whereas that against EBITDA is -577.362.
Stock Price History:
The Beta on a monthly basis for BLFS is 1.96, which has changed by -0.039983988 over the last 52 weeks, in comparison to a change of 0.1276468 over the same period for the S&P500. Over the past 52 weeks, BLFS has reached a high of $29.62, while it has fallen to a 52-week low of $19.10. The 50-Day Moving Average of the stock is -9.17%, while the 200-Day Moving Average is calculated to be -1.24%.
Shares Statistics:
The stock has traded on average 388.84K shares per day over the past 3-months and 403900 shares per day over the last 10 days, according to various share statistics. A total of 47.97M shares are outstanding, with a floating share count of 46.39M. Insiders hold about 3.65% of the company’s shares, while institutions hold 100.99% stake in the company. Shares short for BLFS as of 1761868800 were 3067596 with a Short Ratio of 7.89, compared to 1759190400 on 3688709. Therefore, it implies a Short% of Shares Outstanding of 3067596 and a Short% of Float of 9.0.
Earnings Estimates
Its stock is currently analyzed by 1.0 different market analysts. The consensus estimate for the next quarter is $0.02, with high estimates of $0.02 and low estimates of $0.02.
Analysts are recommending an EPS of between $0.09 and $0.07 for the fiscal current year, implying an average EPS of $0.08. EPS for the following year is $0.16, with 1.0 analysts recommending between $0.16 and $0.16.
Revenue Estimates
8 analysts predict $24.05M in revenue for . The current quarter. It ranges from a high estimate of $24.5M to a low estimate of $23.55M. As of . The current estimate, Biolife Solutions Inc’s year-ago sales were $22.71MFor the next quarter, 8 analysts are estimating revenue of $25.62M. There is a high estimate of $26.2M for the next quarter, whereas the lowest estimate is $25.02M.
A total of 8 analysts have provided revenue estimates for BLFS’s current fiscal year. The highest revenue estimate was $101.53M, while the lowest revenue estimate was $95M, resulting in an average revenue estimate of $96.24M. In the same quarter a year ago, actual revenue was $82.25MBased on 8 analysts’ estimates, the company’s revenue will be $110.87M in the next fiscal year. The high estimate is $114M and the low estimate is $107.5M.
